ZyVersa TherapeuticsNASDAQ: ZVSA

KEY HIGHLIGHTS Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease on track to begin H2-2024. Obesity with related metabolic complications selected as lead indication for Inflammasome ASC Inhibitor IC 100.

ZyVersa CEO will discuss development milestones for Cholesterol Efflux Mediator VAR 200 and Inflammasome ASC Inhibitor IC 100 at BIO CEO & Investor Conf.

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Thursday after the clinical-stage biopharmaceutical company priced a public share offering. ZyVersa Therapeutics is offering 4 million shares of ZVSA stock at a price of $1.25 each.

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is rising higher on Wednesday after the clinical-stage specialty biopharmaceutical company highlighted the publication of a paper in a peer-reviewed journal. That paper, titled “Hematopoietic NLRP3 and AIM2 inflammasomes promote diabetes-accelerated atherosclerosis, but increased necrosis is independent of pyroptosis,” was published in Diabetes.

ZyVersa Therapeutics (NASDAQ: ZVSA ) stock is sliding lower on Wednesday following a couple of announcements from the company. The first is the company's publication of an article in the peer-reviewed Journal of Neuroinflammation.

WESTON, Fla., April 11, 2023 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA, or “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for the treatment of renal and inflammatory diseases with high unmet medical needs, announces that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President, will present at Planet MicroCap Showcase 2023 being held in Las Vegas April 25-27.